Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 62, Issue 15, Pages 6876-6893Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b00719
Keywords
-
Categories
Ask authors/readers for more resources
The hypoxia-inducible factor 2 alpha (HIF-2 alpha) is a key oncogenic driver in clear cell renal cell carcinoma (ccRCC). Our first HIF-2 alpha inhibitor PT2385 demonstrated promising proof of concept clinical activity in heavily pretreated advanced ccRCC patients. However, PT2385 was restricted by variable and dose-limited pharmacokinetics resulting from extensive metabolism of PT2385 to its glucuronide metabolite. Herein we describe the discovery of second-generation HIF-2 alpha inhibitor PT2977 with increased potency and improved pharmacokinetic profile achieved by reduction of phase 2 metabolism. Structural modification by changing the geminal difluoro group in PT2385 to a vicinal difluoro group resulted in enhanced potency, decreased lipophilicity, and significantly improved pharmacokinetic properties. In a phase 1 dose-escalation study, the clinical pharmacokinetics for PT2977 supports the hypothesis that attenuating the rate of glucuronidation would improve exposure and reduce variability in patients. Early evidence of clinical activity shows promise for PT2977 in the treatment of ccRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available